1Roh H, Pippin JA, Green DW, et al. HER2/neu antisense targeting of human breast carcinoma. Oncogene,2000,9 (53) :6138 - 6143.
2Lang I,Hitre E. Trastuzumab (Herceptin) in the adjuvant treatment of HER - 2 - positive early breast cancer. Magy Onkol,2006,50 (4) : 293 - 302
3Hurley J, Doliny P, Reis I, et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2 - positive locally advanced breast cancer. J Clin Oncol, 2006,24( 12 ) : 1831 - 1838
4Paik S, Bryant J, Park C,et al. erbB - 2 and response to doxorubicin in patients with axillary lymph node - positive, hormone receptor - negative breast cancer. J Natl Cancer Inst, 1998,90 ( 18 ) : 1361 - 1370
5Thor AD, Berry DA, Budman DR,et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node -positive breast cancer. J Natl Cancer Inst, 1998,90 ( 18 ) : 1346 - 1360
6Konecny G, Fritz M, Untch M, et al. HER -2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer. Breast Cancer Res Treat,2001,69( 1 ) :53 -63
7Jarvinen TA, Liu ET. Simultaneous amplification of HER - 2 (ERBB2) and topoisomerase Ⅱalpha (TOP2A) genes molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets, 2006,6 (7) :579 - 602
8Kim R, Tanabe K, Uchida Y,et al. The role of HER -2 oncoprotein in drug- sensitivity in breast cancer. Oncol Rep,2002,9( 1 ) :3 -9
